Gout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools JointsAflame
|
|
- Geoffrey Blake
- 6 years ago
- Views:
Transcription
1 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame Paul P. Doghramji, MD, FAAFP Family Physician Collegeville Family Practice Medical Director of Health Services Ursinus College Collegeville, PA Brian Koffman, MDCM Medical Director, CLL Society Inc. Partner, St. Jude Heritage Medical Group Diamond Bar, CA Clinical Professor (Retired) Department of Family Medicine Keck School of Medicine, USC Family Practice Los Angeles, CA QS Priorities 1. Patient Safety: Making care safer by reducing harm caused in the delivery of care 2. Patient and Caregiver Engagement: Ensuring that each person and family are engaged as partners in their care 3. Coordination of Care: Promoting effective communication and coordination of care 4. Dissemination of Best Practices: Promoting the most effective prevention and treatment practices for the leading causes of mortality 5. Population and public health: Working with communities to promote wide use of best practices to enable healthy living 6. Efficient use of healthcare resources: Making quality care more affordable for individuals, families, employers, and governments by developing and spreading new health care delivery models Patients and Providers View Gout Differently Providers view gout medication adherence as good - providing excellent relief In actuality, gout medication adherence is poor Less than 36% Patients discontinue gout meds Patients think ULT worsens or has no impact on gout Do not recognize long-term value DC therapy due to clinical and cost concerns Patients don t understand the concept of treatment goal Gout and The Patient Significant morbidity Work-related disability Loss of productivity Increase healthcare costs All-cause hospital admissions Reach G. Joint Bone Spine. 2011;78: Harrold LR, et al. Chronic Illn : Coburn BW et al. Target Serum Urate- Do Gout Patients Know their Goal? 2016 Arth Care Res68(7): DC, discontinue ULT, urate lowering therapy Rimler E, Lom J, Higdon, Cosco D, Jones D. A Primary Care Perspective on Gout 2016 pen Urol & eph Journ: 9, (Suppl 1:M5) Diet Recommendations Weight loss or 5%-10% goal Reduce or eliminate alcohol Drink lots of water and/or other non-alcoholic fluids Increase low- or non-fat dairy Increase plant-based proteins Beans, legumes Avoid high-purine foods rgan meats ily fish Asparagus/cauliflower Mushrooms ACR Recommendations and Healthline The Economics behind Achieving Gout Goals Year Study Authors Title Factor Cost 2013 Rao S, Haji A, Burns L, Choi H 2015 Rai SK, Lindsay CB, De Vera MA, Haji A, Giustini D, Choi HK 2016 Lim Sy, Lu, za A, Fisher M, Rai SK, Menendez ME, Choi HK The Economic Burden of Gout: A Systematic Review of Direct and Indirect Costs (Boston U. and Univ. of British Columbia) The Economic Burden of Gout: A systematic review -Work productivity loss with >3 flares/yr -Gout related healthcare costs with 6+ flares/yr All-cause direct costs Employed Elderly Treatmentrefractory $ 2,000+ per patient $ 12,000+ per patient Gout on-gout $ 4,400 $ 2,560 $ 17,000 $10,600 $ 18,400 $ 7,200 Trends in Gout & Rheumatoid Arthritis Hosps. In the US Inflation-adjusted annual hospitalization costs for gout (+68%) Gout admissions $ 58,003 Preventableinadequate or inefficient care MEDX Mid-Atlantic ctober 15,
2 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Knowledge Gaps in Patients Patient Engagement Clear understanding of progression Recurrent flares result in chronic joint damage Treatment options and duration of therapy for acute and chronic gout Concept of ULT to avoid complications and disability Treatment goals Accountability starts with an informed patient Improves patient satisfaction with therapy decision Promotes adherence to therapeutic regimen and medication Khanna P et al. Knowledge Gaps In Patients with Gout- A Qualitative Study ACR/ARHP Annual Meeting. Coburn BW et al. Target Serum Urate- Do Gout Patients Know their Goal? 2016 Arth Care Res68(7): Patient Education Goals in Gout Patients want to know more 1 Causes of gout Treatment goals Long-term consequences Exercise for overall health, joint mobility, and weight maintenance 2 Diet Medication adherence tips Physical Activity Goals CDC 2015 Arthritis improves with physical activity Adult goals 150 minutes moderate-intensity/ week plus Muscle strengthening 2 or more days/week lder adult goals minutes moderate-intensity/ week plus Muscle strengthening 2 or more days/week Physical disability Refer to physical therapist 1. nna M, Hinsenveld E, de Vries H, Boonen A. Health Literacy in patients dealing with gout Clin Rhematol.ogy 34(9): Khanna D, et al. Arthritis Care Res. 2012;64: CDC 2015 Gout Goals ACR: Diet Recommendations Avoid Limit Encourage rgan meats high in purine content non-fat dairy products Serving sizes of: Low-fat or (sweetbreads, liver, kidney) Beef, Lamb, Pork Seafood with high purine content B B B (sardines, shellfish) Servings of naturally High fructose corn syrup - sweetened sweet fruit juices Vegetables, Cherries sodas, other beverages, or foods Table sugar, and sweetened beverages and desserts Table salt, including in sauces C and gravies C C Alcohol overuse (defined as more than 2 Alcohol (particularly beer, but also wine servings per day for a male and 1 serving and spirits) in all gout patients per day for a female) in all gout patients B B Any alcohol use in gout during periods of frequent gout attacks, or advanced gout under poor control C The Patient - Achieving Gout Goals All of these points are welltaken, but how do we engage patients to change by understanding their goals and becoming ACTIVATED? Khanna D, et al. Arthritis Care Res. 2012;64: MEDX Mid-Atlantic ctober 15,
3 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Why is SDM Valuable? Shared Decision-Making Enhances provider patient relationship and communication nly 4 of 10 Medicare patients feel their preferences are considered 1 Improves medication adherence 2 Understand risk/benefit Know value of therapy Decreases costs of care 3 Fewer unnecessary tests performed Improves patient satisfaction with therapy 4 1 Covinsky KE, et al. J Am Geriatr Soc. 2000;48(5 Suppl):S187-S Ratanawongsa, et al. JAMA Intern Med. 2013;173: shima LE, et al.. Engl J Med. 2013;368: Barry MJ, et al. Engl J Med. 2012;366: A process by which providers and patients make health care decisions together Aligns medical care with patient preferences and values A core tenet of patient centered care and quality improvement SDM required for Medicare Shared Savings Shared decision-making aids crucial to decision process Whoa way too much information! Shared Decision-Making Process SDM Tool Provider Medical evidence and information Therapeutic options Patient-friendly terms Patient eeds, values, preferences for therapy Decision Care plan Follow-up SDM Aid: Interactive Patient Education Websites Gout and Uric Acid Education Society CFIDETIAL FR ITERAL USE LY MEDX Mid-Atlantic ctober 15,
4 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Gout and the Provider Most cases of gout are treated in the primary care setting 1 Recent survey found opportunities for gout management and treatment 2 Education re achievement of gout goals Implement office monitoring SUA (serum uric acid) Comorbidities ULT re comorbidities Where Does Urate Come From? About two-thirds of uric acid is generated endogenously by the body, while one-third comes from purines in the diet 1 Purine Catabolism 2-4 o Uricase in Humans and Higher Primates 1. Becker MA, Schumacher HR, Romain PL Treatment of Acute Gout; 2016 UpToDate; UpToDate.com 2. Zychowicz M, Howson A, Kim D. et al. Improving gout management in primary care AAFP ational Conference Poster. 1 Fam AG. J Rheum. 2002;29: ; 2 Hediger MA, et al. Physiology. 2005;20: ; 3 Johnson RJ, et al. J Comp Physiol B. 2009;179:67-76; 4 Terkeltaub RA. In: Primer on the Rheumatic Diseases. 12 th ed. Atlanta, GA: Arthritis Foundation; 2001: Gout Risk Factors Diagnosing Gout nly 50% of Gout patients have a dedicated office visit or are treated in first 6 months Advancing age Male gender Family history of gout besity Certain drugs: diuretics, low dose aspirin, cyclosporin Alcohol, especially beer and binge drinking Lead toxicity rgan transplants Thyroid problems ther serious illness Singh JA, Reddy SG, Kundukulam J. Risk Factors for Gout and Prevention 2011 Curr pin Rheum 23(2): Common S&S Joint swelling Intense pain in one or two joints Pain free times between attacks Uric Acid Levels Low or normal during attack >6.0 Imaging X-rays, CT Scan, Ultrasound Joint damage Joint Aspiration Urate crystals Zhang W, et al. Ann Rheum Dis. 2006;65: Differential Diagnosis Rule out other conditions Pseudogout Calcific tendinitis Septic arthritis Psoriatic arthritis, spondyloarthropathy steoarthritis of the first MTP joint or with nodal A of small hand joints Rheumatoid arthritis Cellulitis Lyme disease Trauma ACR, American College of Rheumatology EULAR, European League Against Rheumatism A, osteoarthritis Joint Aspiration: Ideal vs Practical Ideal Provides definitive diagnosis Reality Joint fluid is aspirated only in ~10% of gout cases in primary care; diagnosis is made by the clinical presentation Presumptive Triad of acute monoarticular arthritis, hyperuricemia, and dramatic response to colchicine Recommendations If there is reasonable doubt about the diagnosis, aspirate the joint (or refer for aspiration), especially if septic arthritis suspected ACR Clinical Symposia: Developing ACR Guidelines for the Treatment of Gout ACR/ARHP Annual Scientific Meeting. ov 8, 2011;Chicago, IL. Comorbidities in Gout Individuals in the US general population with gout and hyperuricemia have significantly higher comorbidities 1 Comorbidities Gout- Hyperuricemia o Gout- o Hyperuricemia Hypertension besity Diabetes ephrolithiasis Myocardial infarction Heart Failure Stroke Renal Impairment Zhu Y, et al. Am J Med Jul;125: e1. MEDX Mid-Atlantic ctober 15,
5 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance CKD Associated With Gout 71% of US patients with gout have stage 2 or higher CKD 1 Annual reduction in GFR Healthy adults ml/min Untreated hyperuricemic adults 2.5 ml/min/1.73 m2 1 Martillo M, Karis E, Crittenden db, Pillinger MH Gout Co-Morbidities: Prev. and Mgmt Future Med Clinical Guidelines Underutilized in Gout nly 52.8% of PCPs provide optimal medication therapy for acute gout attacks <20% of PCPs recommended optimal Tx for tophaceous gout <20% of PCPs use ULT with dose titration and prophylaxis Harrold LR, et al. Rheumatology. 2013;6: Edwards L. Curr Rheumatol Rep. 2011;13: Acute and Chronic Gout Therapy is Suboptimal Anti-inflammatory drugs for gout attacks underdosed Patients dissatisfied and non-adherent as a result Long-term ULT value to prevent joint destruction not understood by patients or providers ACR: Therapy and Prevention of Acute Flares Gouty arthritis attack (acute flare) Reduce pain, inflammation, and disability quickly Treat with pharmacologic therapy within 24 hours of onset Treatment for Acute Gouty Inflammation First-line options 1-3 In 2008, the FDA withdrew SAIDs* IV colchicine from the market due to ral Colchicine inappropriate use and deaths. Glucocorticosteroids* Intra-articular Parenteral* Combinations if severe or refractory Medication Considerations for Acute Flare Treatment Risk of GI bleeding (SAID use) Cardiovascular disease (SAID use) Kidney health (SAID and colchicine use) Diabetes (systemic steroid use) 1 Terkeltaub RA. Eng J Med. 2003;349: Terkeltaub R. at Rev Rheumatol. 2010;6: Terkeltaub RA, et al. Arthritis Rheum. 2010;62: *Refer to package insert for adverse events and safety data MEDX Mid-Atlantic ctober 15,
6 Subjects with at Least ne Flare in a 4-week period (%) Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Gout Flare Risk Increases With ULT Expect gout flares with all ULT strategies, especially in first 6 months of treatment Remain on ULT during flares Flares indicate effective ULT due to tophus remodeling Manage flares Initiate prophylaxis 1-2 weeks before starting ULT Important: unexpected flares decrease compliance with ULT - educate patient! Becker MA, et al. Eng J Med. 2005;353: Gout Flares: Febuxostat vs Gouty arthritis flares peak when prophylactic colchicine is stopped at 8 weeks Day 1 - wk Period Febuxostat, 120 mg Febuxostat, 80 mg, 300 mg Subjects Requiring Treatment for Gout Flares The percentage of subjects in each interval is calculated by dividing the number of subjects with at least one gout flare in that interval by the number of subjects exposed to at least one dose of drug in that interval. Subjects may be counted in more than one interval. Subjects received prophylaxis during the period from day 1 to week 8. Results for 80 mg febuxostat group are shown in red, those for 120 mg febuxostat group in blue, and those for 300 mg allopurinol group in green. Becker MA, et al. Eng J Med. 2005;353: Treating Gout Flares: Key Points Flare Management: SAIDS When you start therapy is more important than which agent you use (ACR recommends 24 hours) Select agent considering patient comorbidities The sooner treatment is initiated after symptoms begin, the faster it will work When taken at the earliest hint of a flare, attacks may be aborted with one dose Wortmann PL, et al. Gout and hyperuricemia. In: Harris ED Jr, et al, eds. Kelly s Textbook of Rheumatology. 7 th ed. Philadelphia, PA: WB Saunders Company; 2005: Take as soon as symptoms begin, such as Ibuprofen* aproxen* Indomethacin* Determine the correct dose with the patient Should not be used in: 1 Gastric bleeding Renal failure Heart failure Gastric AE s 2 Proton pump inhibitor may be given 1 Winzenberg T, et al. J Fam Pract. 2009;58(7):E Laine L. Rev Gastroenterol Disord. 2003;3 Suppl 4:S30-S39. *Refer to package insert for adverse events and safety data AE s, adverse events Flare Management: Colchicine ral colchicine used in two situations: Acute Flare Dose adjustment in CKD and/or drug interaction, unless lack of tolerance or medical contraindication Flare Prophylaxis Colchicine 0.6 daily or bid for 3-6 months or longer ote: Chronic use of colchicine among gout patients linked with a decreased risk of myocardial infarction ral Colchicine Dosing Guidelines for Acute Gout Colchicine 0.5 mg TID daily for 1-3 days AGREE trial: Large, randomized, double-blind, placebo-controlled trial (n=184 patients treated for early gout flares [<12 hours]) 2 Low-dose colchicine 1.2 mg, and then 0.6 mg 1 hour later (1.8 mg total), equally effective and better tolerated than high-dose colchicine 1.2 mg, then 0.6 mg hourly x 6 hours (4.8 mg total) (P<0.05) Khanna D, et al. Arthritis Care Res. 2012;64: CKD, chronic kidney disease 1 Zhang W, et al. Ann Rheum Dis. 2006;65: Terkeltaub RA, et al. Arthritis Rheum. 2010;62: MEDX Mid-Atlantic ctober 15,
7 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Treat to Goal Serum Urate Lowering Goal Serum urate level should be lowered sufficiently to prevent gout attacks Target <6.0 mg/dl at a minimum Target <5.0 mg/dlif tophi or still getting attacks if <6.0 In Europe, target is <5.0 Uricosuric Pharmacologic Urate-lowering Strategies Increase uric acid elimination: eg, target proximal tubule epithelial cell transporters using probenecid Uricostatic Suppress uric acid formation: eg, target xanthine oxidase using allopurinol or febuxostat Uricolytic biologic approach Directly degrade soluble urate: pegloticase Khanna D, et al. Arthritis Care Res. 2012;64: Terkeltaub R. at Rev Rheumatol. 2010;6: Uricosuric-Probenecid Uricosurics: thers nly FDA-approved agent currently available Typical dosing: 500 mg BID titrated up to 2.5 g a day Usage First line if XI can t be used Second line: added to XI if target not reached ot effective with egfr <50 Contraindicated with uric acid overproduction Activity blocked by ASA Side effects common 1 Urolithiasis risk onspecific GI, CS side effects Rash, drug-drug interactions Losartan, fenofibrate, atorvastatin: all off label Good added options in hyperlipidemia and hypertension if indicated Relatively weak effects Lesinurad In phase 3 clinical trials Approved - not yet available 1 Reinders MK, et al. Ann Rheum Dis. 2009;68: XI, xanthine oxidase inhibitor egfr, estimated glomerular filtration rate ASA, aspirin Uricostatic Medications Xanthine oxidase inhibitor (XI) therapy - First Line urate lowering therapy (ULT) Febuxostat Available in US since 1966 Purine-like backbone, converted in liver to oxypurinol Hypoxanthine Xanthine xypurinol Khanna D, et al. Arthritis Care Res. 2012;64: Uric acid ormal half-life 24 hours Renal Elimination MEDX Mid-Atlantic ctober 15,
8 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Starting dosage of allopurinol should be no greater than 100 mg/day and less than that in moderate to severe CKD Gradual upward titration of the maintenance dose, which can exceed 300 mg daily even in patient with CKD Most common ULT in US Pruritic rash in ~2%; intolerance in 5%-10% (eg, hepatic enzyme elevation, GI, CS) Major cutaneous reactions (SJS, TE) linked with HLA-B58 Major allopurinol hypersensitivity syndrome has incidence of 0.1%-0.4%, up to 25% mortality Khanna D, et al. Arthritis Care Res. 2012;64: Riedel AA, et al. J Rheumatol. 2004;31: Chao J, et al. Curr Rheumatol Rep. 2009;11: Terkeltaub R. Recent Advances in Difficult-to-Treat Gout: Medscape ACR 2008 Annual Mtg; San Francisco, CA. GI, gastrointestinal CS, central nervous system SJS, Stevens-Johnson syndrome TE, toxic epidermal necrolysis Dosing Guidelines Initiating ACR, EULAR and FDA Guidelines Start at 100 mg daily, lower in CKD Increase by 100 mg daily every 2 weeks until the target SUA level is reached ~400 mg daily is an average dose to achieve target level in subjects with preserved renal function Divide allopurinol dose to BID at >300 mg daily dose adjustment required in CKD FDA approved at doses up to 800 mg daily (monitor for toxicity) Prior to initiation of allopurinol HLA-B* 5801 screening - risk management High risk ratio Korean with stage 3 or worse CKD Han Chinese Thai HLA-B*5801, human leukocyte antigen Chao J, et al. Curr Rheumatol Rep. 2009;11: Zhang W, et al. Ann Rheum Dis. 2006;65: Khanna D, et al. Arthritis Care Res. 2012;64: Febuxostat: onpurine Xanthine xidase Inhibitor Febuxostat Phase 3 Trials vs ontitrated : Primary Endpoint Serum Urate <6 mg/dl onpurine backbone, selective inhibitor of xanthine oxidase H S C C2H H Febuxostat CH 3 Primarily metabolized in the liver Study CFIRMS 1 (6 months) Febuxostat 40 mg daily 45% (n=757) APEX 2 (6 months) -- FACT 3 (12 months) -- Febuxostat 80 mg daily 67% *, ** (n=756) 76% * (n=267) 53% * (n=256) 300 mg daily Placebo 42% (n=755) -- 41% *** (n=268) * P<.001 vs allopurinol ** P<.001 vs febuxostat 40 mg and placebo *** P<.001 vs placebo 1% (n=134) 21% (n=253) -- Febuxostat prescribing information. 1 Becker MA, et al. Arthritis Res Ther. 2010;12:R63. 2 Schumacher HR, et al. Arthritis Rheum. 2008;59: Becker MA, et al. Eng J Med. 2005;353: MEDX Mid-Atlantic ctober 15,
9 Mean change egfr from BL, ml/min Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Febuxostat Dosing Label: 40 mg daily for 2 weeks. If serum urate does not normalize after 2 weeks, increase to 80 mg daily Dose reduction not needed in moderate renal or liver impairment (CrCL >29 ml/min) Most common side effects: rash (~2%), elevated LFTs (up to 3%), and arthralgia (~1%) LFTs, liver function tests Preservation of Renal Function with Febuxostat Time, y Expected Decline, untreated hyperuricemia All Subjects treated with febuxostat Adapted from Whelton A, et al. Postgrad Med. 2013;125(1): Combining ULT to Reduce Serum Uric Acid When serum urate target has not been met with appropriate dosing of XI Combination of oral ULT with 1 XI agent and 1 uricosuric agent is appropriate Getting to Goal: Combining Urate Lowering Therapies Many on XI s do not achieve <6 mg/dl or <5 mg/dl Medical need for additional options Consideration may be given to combination therapies Khanna D, et al. Arthritis Care Res. 2012;64: Emerging Therapy Lesinurad SURI (selective uric acid reabsorption inhibitor) Recently approved Approved - not yet available Lesinurad: Selective Uric Acid Reabsorption Inhibitor CLEAR 1 and CLEAR 2 Primary End Point Proportion of subjects achieving serum uric acid <6 mg/dl at month 6 (%) LESU200 vs PB (CLEAR 1 and CLEAR 2 combined): RR = 2.15; 95% CI: 1.78, 2.59 LESU400 vs PB (CLEAR 1 and CLEAR 2 combined): RR = 2.46; 95% CI: 2.05, 2.95 t = P <.0001 vs PB + ALL arm CLEAR 1 CLEAR 2 PB + ALL 28 t 23 LESU200 + ALL 54 t 55 t LESU400 + ALL 59 t 67 t PB, placebo Saag KG, et al. Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: Combination Study of Lesinurad in Standard of Care Inadequate Responders (CLEAR 1 and 2) ACR Abstract L10. MEDX Mid-Atlantic ctober 15,
10 Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Managing the Gout Patient Long-Term Prevent gout attacks with prophylaxis flare therapy for first 3-6 months of ULT Maintain normal serum UA with long-term ULT medication Support diet and lifestyle modifications Monitor side effect status of flare medication Measure UA levels Monitor ULT side effects Monitor renal function UA, uric acid Thank you! MEDX Mid-Atlantic ctober 15,
Gout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools JointsAflame
Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame
More informationGout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame
Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Paul P. Doghramji, MD, FAAFP
More informationBEYOND THE FLARE IMPLEMENTING SOLUTIONS FOR HYPERURICEMIA GOAL ACHIEVEMENT IN THE PRIMARY CARE PRACTICE
BEYOD THE FLARE IMPLEMETIG SOLUTIOS FOR HYPERURICEMIA GOAL ACHIEVEMET I THE PRIMARY CARE PRACTICE Paul Doghramji, MD FAAFP Collegeville Family Practice Collegeville, PA 1 APPROXIMATELY HOW MAY GOUT PATIETS
More information1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout
Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.
More informationGout: Update in therapeutics
Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationUloric Step Therapy Program
Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand
More informationOBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE
GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when
More informationAchieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP
Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services
More informationEnhanced Primary Care Pathway: Gout
Enhanced Primary Care Pathway: Gout 1. Focused summary of gout relevant to primary care Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationGout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA
Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationGout Hanan Abdel Rehim
Review article 35 Gout Hanan Abdel Rehim Department of Internal Medicine, Kasr-Al Aini School of Medicine, Cairo University, Cairo, Egypt Correspondence to Hanan Abdel Rehim, MD, 11 Ismaiel Wahby Street,
More informationGout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017
Gout: Let s Be Crystal Clear Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationGout A rapid review. Jeremy Jones
Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGout Treatment Guidelines
Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,
More informationGout: Develop treatment plan in William Jones, MS, RPh
Gout: Develop treatment plan in 2013 William Jones, MS, RPh (wnjones49@cox.net) Objectives Describe acute gouty arthritis Tx Describe Tx of chronic gouty arthritis. Define the target serum uric acid concentration
More informationGOUT. Dr Krishnan Baburaj West herts NHS Trust
GOUT Dr Krishnan Baburaj West herts NHS Trust podagra Gout A disease of kings, the king of diseases History Louis XIV Emperor Augustus Henry VIII Introduction Gout an inflammatory arthritic condition that
More informationA Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.
A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally
More informationRheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy
Rheumatoid arthritis, seronegative spondylarthritides and gout György Nagy Dec 4, 2017 Rheumatoid arthritis Rheumatoid arthritis Chronic, progressive, autoimmune disorder of the joints with extra-articular
More informationLecture 8 Gout Hinch. Pathogenesis of acute attacks
Gout: disease characterized by deposition of monosodium crystals in soft tissues (cartilage, tendons, bursa) recurrent episodes of acute joint pain & inflammation Pathogenesis of acute attacks Epidemiology:
More informationUpdate on Gout for GPs
Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More informationCrystal-Induced Arthritis. Rajesh Kataria, D.O. Southern Ohio Rheumatology
Crystal-Induced Arthritis Rajesh Kataria, D.O. Southern Ohio Rheumatology Disclosures Speaker: Rajesh Kataria, D.O. Relationships with commercial interests: Speakers Bureau - Horizon Presentation will
More information3/2/2014. Got Gout? Get a Plumber. Objectives. Disclosures
Got Gout? Get a Plumber. Heidi Garcia, PA-C Department of Rheumatology Division of Internal Medicine Mayo Clinic Arizona 2013 MFMER slide-1 Objectives Recall some of the history of Gout. Describe the pathophysiology
More informationLong-term Treatment of Gout: New Opportunities for Improved Outcomes
Long-term Treatment of Gout: New Opportunities for Improved Outcomes Paul P. Doghramji, MD, FAAFP CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Make a presumptive diagnosis of gout based on history
More informationLiterature Scan: Analgesics for Gout. Month/Year of Review: April 2015 Date of Last Review: January 2014
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationManaging Gout A Review of the Research for Adults
Managing Gout A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional* has said that you have gout. You are age 18 or
More informationWhat will happen in the future? How will gout be diagnosed? How is gout treated? prevent
Rheumatology Day Unit Dr J Hamilton 0191 4458359 0191 4455240 (9-5 Mon-Fri) Dr C Heycock 0191 4452198 Answer phone on 24hours Dr C Kelly 0191 4452193 Dr V Saravanan 0191 4456055 Dr M Rynne 0191 4458359
More informationGOUT IN THE ELDERLY. Learning Objectives. Disclosure. Geriatric Grand Rounds. Geriatric Grand Rounds
Visit web sites: Tuesday, June 2, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this event
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Gout and Pseudogout Wayne Blount MD Speaker has no disclosures
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationAn update on the management of gout
An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence
More informationCopyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
14 The Nurse Practitioner Vol. 41, No. 14 www.tnpj.com 2.5 CONTACT HOURS 2.5 CONTACT HOURS Gout An update on for primary care providers Abstract: This article discusses the current beliefs regarding the
More informationCurrent treatment options for acute and chronic gout
DRUG REVIEW n Current treatment options for acute and chronic gout Kelsey Jordan FRCP and Andrew Jeffries PGDip, MRCP Gout is the only curable form of arthritis, yet only a third of patients with chronic
More informationDrugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used to Treat Gout Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Gout is a metabolic disease characterized by recurrent episodes of acute arthritis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.PHAR.115 Effective Date: 06.01.13 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationLesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout
Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Briefing Document for the Arthritis Advisory Committee Meeting Date: 23 October 215 Ardea
More informationNew Drugs for the Primary Care Provider: What You Need to Know
4:00 4:35 pm New Drugs for the Primary Care Provider: What You Need to Know SPEAKER Gerald W. Smetana, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationSubject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s):
Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13 Policy Number: MCP-138 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationGOUT GO FOR SIX WITH. Everything You Need to Know About Gout & Uric Acid PLUS:
GO FOR SIX WITH Everything You Need to Know About Gout & Uric Acid GOUT PLUS: How to gain control of symptoms A gout-friendly eating style Medication recommendations to discuss with your doctor Lifestyle
More informationRetreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
Rheumatol Ther (2018) 5:583 594 https://doi.org/10.1007/s40744-018-0111-9 CASE SERIES Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases Allan H. Morton.
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationZurampic. (lesinurad) New Product Slideshow
Zurampic (lesinurad) New Product Slideshow Introduction Brand name: Zurampic Generic name: Lesinurad Pharmacological class: URAT1 inhibitor Strength and Formulation: 200mg; tablets Manufacturer: Ironwood
More informationImplementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices
Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Gout: Diagnosis and Management Practice Pointers by MATTHEW R. NOSS, DO, MSEd, U.S. Army Health Clinic,
More informationGout basics. Update on Gout. Production of uric acid. Gout basics. Crystal induced inflammation. Gout calculator. The important role of ultrasound
Update on Gout The important role of ultrasound Cheung C Yue, M.D. Gout basics Hyperuricemia gout Over 5 years, 22% >9 mg/dl develop gout Man 3-4 times more than women Risks: thiazide, cyclosporin, low
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PEGLOTICASE KRYSTEXXA 37154 GUIDELINES FOR USE 1. Does the patient have a diagnosis of symptomatic chronic gout (prior to initiating Krystexxa therapy) with clinical
More informationPodcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam. Howard J. Sachs, MD
Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded Lecture Series): Gout for the
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationDiagnosis and Management of Gout in 2011
October 18, 2011 Early and accurate gout diagnosis and disease management are essential. Making the clinical diagnosis takes into consideration the differential diagnosis supported by the use of clinical,
More informationCrystal induced arthropathies. Dr. Amitesh Aggarwal
Crystal induced arthropathies Dr. Amitesh Aggarwal 1 Crystal induced Arthropathies Gout Pseudogout Debilitating illnesses; Recurrent episodes of pain and joint inflammation; Formation and deposition of
More informationClass Update: Drugs for Gout
Copyright 2012 Oregon State University. ll Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.CPA.57 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationEssence of the Revised Guideline for the Management of Hyperuricemia and Gout
Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of
More informationGout Prevention Project. Simplifying Gout Prevention Management for GPs and Patients
Gout Prevention Project Simplifying Gout Prevention Management for GPs and Patients Gout Prevalance 2 Gout Management primary care level 52.8% of PCP provided optimal medication treatment for acute attack
More informationFebuxostat: a new treatment for hyperuricaemia in gout
Rheumatology 2009;48:ii15 ii19 doi:10.1093/rheumatology/kep088 Febuxostat: a new treatment for hyperuricaemia in gout N. Lawrence Edwards 1 Febuxostat is a new non-purine xanthine oxidase inhibitor that
More informationDose of celecoxib in gout attack attack
Dose of celecoxib in gout attack Gout is a disease characterized by an abnormal metabolism of uric acid, resulting in an excess of uric acid in the tissues and blood. People with gout either produce too
More informationCOMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT
Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF
More informationStudy of Febuxostat for the Management of Hyperuricemia in Gout
Human Journals Review Article October 2015 Vol.:4, Issue:3 All rights are reserved by Sachin S. Shinde et al. Study of Febuxostat for the Management of Hyperuricemia in Gout Keywords: Febuxostat, Hyperuricemia,
More informationGOUT GO FOR SIX WITH. Everything You Need to Know about Gout & Uric Acid PLUS:
GO FOR SIX WITH Everything You Need to Know about Gout & Uric Acid GOUT PLUS: How to gain control of symptoms A gout-friendly eating style Medication recommendations to discuss with your doctor Lifestyle
More informationFor more information about how to cite these materials visit
Author(s): Seetha Monrad, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationPlus: How to gain control of symptoms A gout-friendly eating style Lifestyle changes that can help prevent future attacks
about Gout What You Need to Know about Gout & Uric Acid Plus: How to gain control of symptoms A gout-friendly eating style Lifestyle changes that can help prevent future attacks We re doing everything
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationuric acid Non electrolytes of the plasma
73 uric acid Non electrolytes of the plasma 1 Purines and uric acid Fig 2 JFI Uric acid is the major product of catabolism of the purine nucleosides adenosine and guanosine, Uric acid is sparingly soluble
More informationNovel uricosurics RHEUMATOLOGY. Thomas Bardin 1,2 and Pascal Richette 1,2. Abstract. Introduction REVIEW
RHEUMATOLOGY Rheumatology 2018;57:i42 i46 doi:10.1093/rheumatology/kex433 Novel uricosurics Thomas Bardin 1,2 and Pascal Richette 1,2 REVIEW Abstract Objective. According to recent guidelines, the mainstay
More informationMono-articular Joint Complaints
Mono-articular Joint Complaints Derrick J. Todd, M.D., Ph.D. Associate Physician Department of Rheumatology, Immunology, and Allergy Brigham and Women s Hospital Instructor of Medicine Harvard Medical
More informationClinical Practice Guideline. Gout. Version
Clinical Practice Guideline Gout Version 1.1.2017 August 2017 Table of Contents Introduction...5 Stages of Gout...7 Asymptomatic Hyperuricemia... 7 Acute Intermittent Gout... 7 Advanced Gout... 8 Diagnosis...8
More informationFebuxostat: a safe and effective therapy for hyperuricemia and gout
DRUG EVALUATIO Febuxostat: a safe and effective therapy for hyperuricemia and gout atasha Jordan & Geraldine M McCarthy Author for correspondence Mater Misericordiae University Hospital, Eccles St. Dublin
More informationUniversity of Groningen
University of Groningen Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients Reinders, M.K.; van Roon, Eric; Houtman, Pieternella; Brouwers,
More informationKrystexxa (pegloticase) Document Number: IC-0158
Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length
More informationpegloticase (Krystexxa )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective Observational Study
International Rheumatology, Article ID 123105, 6 pages http://dx.doi.org/10.1155/2014/123105 Clinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 24 June 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 24 June 2009 ADENURIC 80 mg, film-coated tablets B/28 (CIP code: 385 724-4) B/84 (CIP code: 572 820-3) ADENURIC 120
More informationZurampic, Duzallo (lesinurad Products)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationLECTURE 5: DRUGS IN GOUT
Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Green : Dr s notes Grey: Extra information, explanation Editing File LECTURE 5: DRUGS IN GOUT
More informationKrystexxa. Krystexxa (pegloticase) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.14 Subject: Krystexxa Page: 1 of 5 Last Review Date: March 16, 2018 Krystexxa Description Krystexxa
More informationTherapy for Gout: The Past
Advances in Therapy for Gout: 2011 The Past, Present, and Future Therapy for Gout: The Past May 22, 1997 Pity a Tyrannosaur? Sue Had Gout By MALCOLM W. BROWNE Jonathan Graf, M.D. Associate Professor of
More informationClinical Policy: Colchicine (Colcrys) Reference Number: CP.PPA.11. Line of Business: Medicaid
Clinical Policy: (Colcrys) Reference Number: CP.PPA.11 Effective Date: 05/11 Last Review Date: 05/176 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationMEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011
Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY PREAUTHORIZATION REQUIRED Note: Requests for pegloticase
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationCHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:2 GOUT BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY DEFINITION Gout is defined as a peripheral arthritis, resulting from the deposition of MSU crystals
More informationGout: A Clinical Update. Why talk about Gout? Why talk about Gout? Populations at risk: Why is Gout Less Common in Women? US Gout Population: 2009
Gout: A Clinical Update Peng Thim Fan, MD, FACP Clinical Professor of Medicine Division of Rheumatology David Geffen School of Medicine at UCLA Why talk about Gout? Large increase in gout in the last 20
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More information4/1/2011. New Developments in Gout. Conflict of Interest Declaration. Objectives
New Developments in Gout Tatum N. Mead, Pharm.D. Clinical Assistant Professor UMKC SOP meadt@umkc.edu April 16, 2011 1 Conflict of Interest Declaration I have no actual or potential conflict of interest
More informationWomen With Gout: Efficacy and Safety of Urate-Lowering With Febuxostat and Allopurinol
Arthritis Care & Research Vol. 64, No. 2, February 2012, pp 256 261 DOI 10.1002/acr.20680 2012, American College of Rheumatology ORIGINAL ARTICLE Women With Gout: Efficacy and Safety of Urate-Lowering
More informationGout. Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 CLINICAL REVIEW
Gout Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 1 Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele ST5 5BG, UK 2 Academic Rheumatology, University
More informationD espite reasonable understanding of its pathogenesis
1312 EXTENDED REPORT EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics
More informationCOPYRIGHT. Update in Internal Medicine December 4, 2016
Update in Internal Medicine December 4, 2016 Fadi Badlissi, MD, MSc Director of the Musculoskeletal Medicine Unit The Orthopedic Department & Rheumatology Division Beth Israel Deaconess Medical Center
More informationJournal of Advanced Scientific Research
Bijoy Kumar Panda et al, J Adv Scient Res, 2012, 3(2): 03-11 3 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Review Article Febuxostat,
More informationN Engl J Med 2018;378: DOI: /NEJMoa Lin, Wan-Ting 2018/06/27
N Engl J Med 2018;378:1200-10. DOI: 10.1056/NEJMoa1710895 Lin, Wan-Ting 2018/06/27 1 Introduction Gout is a chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis
More information